新诊断多发性骨髓瘤患者中自体造血干细胞移植对比卡非佐米-环磷酰胺-地塞米松巩固联合卡非佐米维持治疗(CARDAMON):一项随机、2期、非劣效性试验
CARDAMON研究在英格兰和威尔士19家医院纳入281例新诊断、适合移植的多发性骨髓瘤患者,接受4周期KCd诱导后随机分为自体HSCT组或4周期KCd巩固组,均接受18周期卡非佐米维持。2年无进展生存率HSCT组75% vs KCd组68%(差异-7.2%,70%CI -11.1至-2.8),超过10%非劣效界值,KCd未达非劣效。
要点
- 诱导后57.7%患者达≥非常好的部分缓解。
- 2年PFS:HSCT组75% vs KCd组68%,差异-7.2%,未达非劣效。
- KCd巩固组常见3-4级不良事件为淋巴细胞减少和感染。
核心结论
- KCd方案未达到与自体HSCT相比的非劣效性标准,但PFS的边缘差异提示需进一步研究在某些亚组(如诱导后MRD阴性者)中延迟自体HSCT。
研究设计与样本
- CARDAMON是一项在英格兰和威尔士19家医院开展的随机、开放标签、2期非劣效性试验,纳入281例新诊断、适合移植的多发性骨髓瘤患者。
- 患者接受4周期KCd诱导后,≥部分缓解者按1:1随机分配至自体HSCT组或4周期KCd巩固组,所有随机患者接受18周期卡非佐米维持治疗。
- 主要终点为诱导后≥非常好的部分缓解比例和随机后2年无进展生存率差异(非劣效界值10%),均按意向性治疗分析。
主要发现
- 2015年6月16日至2019年7月8日共入组281例患者,218例进入随机(KCd巩固组109例,HSCT组109例)。
- 诱导后162例(57.7%;95%CI 51.6至63.5)281例患者达≥非常好的部分缓解。
- 2年无进展生存率HSCT组75%(95%CI 65至82)vs KCd组68%(95%CI 58至76),差异-7.2%(70%CI -11.1至-2.8),超过非劣效界值。
- KCd诱导和巩固期间最常见3-4级事件为淋巴细胞减少(诱导278例中72例[26%];巩固109例中15例[14%])和感染(诱导50例[18%];巩固15例[14%])。
- 卡非佐米维持期间最常见3-4级事件为高血压(KCd巩固组97例中20例[21%] vs HSCT组99例中23例[23%])和感染(16例[16%] vs 25例[25%])。
关键数值与推荐
- 非劣效界值为10%。
- 2年无进展生存率差异为-7.2%(70%CI -11.1至-2.8),超过非劣效界值。
临床怎么用
- KCd方案未达到与自体HSCT相比的非劣效性标准。
- 作者认为PFS的边缘差异提示需进一步研究在某些亚组(如诱导后MRD阴性者)中延迟自体HSCT。
局限性
- KCd未达到非劣效性标准,但PFS的边缘差异提示需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Standard-of-care treatment for patients with newly diagnosed multiple myeloma is bortezomib-based induction followed by high-dose melphalan and autologous haematopoietic stem-cell transplantation (HSCT) and lenalidomide maintenance. We aimed to evaluate whether an immunomodulatory-free carfilzomib-based induction, consolidation, and maintenance protocol without autologous HSCT was non-inferior to the same induction regimen followed by autologous HSCT and maintenance. METHODS: CARDAMON is a randomised, open-label, phase 2 trial in 19 hospitals in England and Wales, UK. Newly diagnosed, transplantation-eligible patients with multiple myeloma aged 18 years or older with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 received four 28-day cycles of carfilzomib (56 mg/m2 intravenously on days 1, 2, 8, 9, 15, and 16), cyclophosphamide (500 mg orally on days 1, 8, and 15), and dexamethasone (40 mg orally on days 1, 8, 15, and 22; KCd), followed by peripheral blood stem cell mobilisation. Patients with at least a partial response were randomly assigned (1:1) to either high-dose melphalan and autologous HSCT or four cycles of KCd. All randomised patients received 18 cycles of carfilzomib maintenance (56 mg/m2 intravenously on days 1, 8, and 15). The primary outcomes were the proportion of patients with at least a very good partial response after induction and difference in progression-free survival rate at 2 years from randomisation (non-inferiority margin 10%), both assessed by intention to treat. Safety was assessed in all patients who started treatment. The trial is registered with ClinicalTrials.gov (NCT02315716); recruitment is complete and all patients are in follow-up. FINDINGS: Between June 16, 2015, and July 8, 2019, 281 patients were enrolled, with 218 proceeding to randomisation (109 assigned to the KCd consolidation group [99 of whom completed consolidation] and 109 to the HSCT group [104 of whom underwent transplantation]). A further seven patients withdrew before initiation of carfilzomib maintenance (two in the KCd consolidation group vs five in the HSCT group). Median age was 59 years (IQR 52 to 64); 166 (59%) of 281 patients were male and 115 (41%) were female. 152 (71%) of 214 patients with known ethnicity were White, 37 (17%) were Black, 18 (8%) were Asian, 5 (2%) identified as Mixed, and 2 (1%) identified as other. Median follow-up from randomisation was 40·2 months (IQR 32·7 to 51·8). After induction, 162 (57·7%; 95% CI 51·6 to 63·5) of 281 patients had at least a very good partial response. The 2-year progression-free survival was 75% (95% CI 65 to 82) in the HSCT group versus 68% (95% CI 58 to 76) in the KCd group (difference -7·2%, 70% CI -11·1 to -2·8), exceeding the non-inferiority margin. The most common grade 3-4 events during KCd induction and consolidation were lymphocytopenia (72 [26%] of 278 patients who started induction; 15 [14%] of 109 patients who started consolidation) and infection (50 [18%] of 278 for induction; 15 [14%] of 109 for consolidation), and during carfilzomib maintenance were hypertension (20 [21%] of 97 patients in the KCd consolidation group vs 23 [23%] of 99 patients in the HSCT group) and infection (16 [16%] of 97 patients vs 25 [25%] of 99). Treatment-related serious adverse events at any point during the trial were reported in 109 (39%) of 278 patients who started induction, with infections (80 [29%]) being the most common. Treatment-emergent deaths were reported in five (2%) of 278 patients during induction (three from infection, one from cardiac event, and one from renal failure) and one of 99 patients during maintenance after autologous HSCT (oesophageal carcinoma). INTERPRETATION: KCd did not meet the criteria for non-inferiority compared with autologous HSCT, but the marginal difference in progression-free survival suggests that further studies are warranted to explore deferred autologous HSCT in some subgroups, such as individuals who are MRD negative after induction. FUNDING: Cancer Research UK and Amgen.
引用
- Yong K, Wilson W, de Tute RM, et al. Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial. Lancet Haematol. 2022. PMID: 36529145. doi:10.1016/S2352-3026(22)00350-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。